



Docket No. 1151-4175

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Chang Yi Wang et al.

Group Art Unit: TBD

Serial No.: 10/712,812

Examiner: TBD

Filed: November 12, 2003

For: PEPTIDE-BASED DIAGNOSTIC REAGENTS FOR SARS

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop \_\_\_\_\_  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
2. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. \_\_\_\_\_, filed \_\_\_\_\_.
4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:  
☒ 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or

- ☐ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
- ☐ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
- ☐ 37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.
5. ☐ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6. ☐ A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
- ☐ A check in the amount of \$180.00 is enclosed in payment of the fee.
- ☐ Charge the fee to Deposit Account No. 13-4500, Order No. \_\_\_\_\_. A  
DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7. ☐ A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
- a. one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
- b. the fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 below.
8. ☐ This Information Disclosure Statement is being filed in compliance with:
- a. ☐ 37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);
- b. ☐ 37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).
- c. ☐ The fee due under 37 C.F.R. §1.17(h) is paid as set forth in paragraph 11

below.

9. ☐ I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- ☐ I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
10. ☐ This document is accompanied by ☐ a Search Report ☐ Communication which was cited in a corresponding ☐ PCT or ☐ Foreign counterpart application
11. ☐ A check in the amount of \$ \_\_\_\_\_ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).
- ☐ Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 13-4500, Order No. \_\_\_\_\_. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 1151-4175. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: December 5, 2003

By: \_\_\_\_\_



Maria C.H. Lin  
Registration No. 29,323

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, NY 10154-0053  
(212) 758-4800 Telephone  
(212) 751-6849 Facsimile



12-8-03

Docket No. 1151-4175

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Chang Yi Wang et al.

Group Art Unit: TBD

Serial No.: 10/712,812

Examiner: TBD

Filed: November 12, 2003

For: PEPTIDE-BASED DIAGNOSTIC REAGENTS FOR SARS

**EXPRESS MAIL CERTIFICATE**

Express Mail Label No.: EV 357 836 125US

Date of Deposit: December 5, 2003

I hereby certify that the following attached paper(s) and/or fee

1. Information Disclosure Statement;
2. Form PTO-1449;
3. 27 cited references;
4. Return Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450


Susan Shen

(Typed or printed name of person mailing papers(s) and/or fee)

(Signature of person mailing paper(s) and/or fee)

**Correspondence Address:**

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, NY 10154-0053  
(212) 758-4800 Telephone  
(212) 751-6849 Facsimile



Docket No. 1151-4175

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Chang Yi Wang et al.

Group Art TBD

Serial No.: 10/712,812

Examiner: TBD

Filed: November 12, 2003

For: PEPTIDE-BASED DIAGNOSTIC REAGENTS FOR SARS

**IDS COVER SHEET**

1. Severe Acute Respiratory Disease: World Health Organization [www.who.int/csr/sars/en](http://www.who.int/csr/sars/en)
2. CDC. "Updated Interim Surveillance Case Definition for Severe Acute Respiratory Syndrome (SARS)"-- United States, April 29, 2003. *MMWR* 2003; 52:391-393
3. Fouchier RAM, et al., "Koch's Postulates Fulfilled for SARS Virus". *Nature* 2003; 423:240
4. Peiris JSM, et al., "Coronavirus As a Possible Cause of Severe Acute Respiratory Syndrome". *Lancet* 2003; 361:1319-1325
5. National Research Project for SARS Beijing Group. "Serum Antibodies Detection For Serological Diagnosis Of Severe Acute Respiratory Syndrome". *Zhonghua Jie He He Hu Xi Za Zhi* 2003; 26:339-342
6. Li G, et al., "Profile Of Specific Antibodies To The SARS-Associated Coronavirus". *N Eng J Med* 2003; 349:508-509
7. Holmes KV, "Coronaviridae and Their Replication". *Virology* 2nd edition. Vol. 1. New York: Raven Press, 1990:841-864
8. Rota PA, et al., "Characterization Of A Novel Coronavirus Associated With Severe Acute Respiratory Syndrome". *Science* 2003; 300:1394-1398
9. Ruan Y, et al., "Comparative Full-Length Genome Sequence Analysis Of 14 SARS Coronavirus Isolates And Common Mutations Associated With Putative Origins Of Infection". *Lancet* 2003; 361:1779-1785
10. Wang Y, Xie Y, Chen W, "Immunoinformatic Analysis For The Epitopes On SARS Virus Surface Protein". *Beijing Da Xue Xue Bao* 2003; 35:70-71
11. Yu H, et al., "Expression and Purification Of Recombinant SARS Coronavirus Spike Protein". *Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)* 2003; 35:774-778


12. Elia G, et al., "Recombinant M Protein-Based ELISA Test For Detection Of Antibodies To Canine Coronavirus". J Virol Methods 2003; 109:139-142
13. Che XY, et al., "Antibody Response Of Patients With Severe Acute Respiratory Syndrome (SARS) To Nucleocapsid Antigen Of SARS-Associated Coronavirus". Di Yi Jun Yi Da Xue Xue Bao 2003; 23:637-639
14. Krokhn O, et al., "Mass Spectrometric Characterization Of Proteins From The SARS Virus". Mol Cell Proteomics 2003; 2:346-356
15. Wang CY, "Synthetic Peptide-Based Immunodiagnosis Of Retrovirus Infections: Current Status And Future Prospects". Synthetic peptides in biotechnology: 1988:131-148
16. U.S. Patent No. 5,747,239
17. U.S. Patent No. 6,048,538
18. Wang JJG, et al., "Detection of Antibodies To Human T-Lymphotropic Virus Type III By Using A Synthetic Peptide Of 21 Amino Acid Residues Corresponding To A Highly Antigenic Segment Of Gp41 Envelope Protein". Proc Nat Acad Sci USA 1986; 83:6159-6163
19. Hosein B, et al., "Improved Serodiagnosis Of Hepatitis C Virus Infection With Synthetic Peptide Antigen From Capsid Protein". Proc Nat Acad Sci USA 1991; 88:3647-3651
20. U.S. Patent No. 5,639,594
21. U.S. Patent No. 5,681,696
22. Shen F, et al., "Differentiation of Convalescent Animals From Those Vaccinated Against Foot-And-Mouth Disease By A Peptide ELISA". Vaccine 1999; 17:3039-3049
23. Marra MA, et al., "The Genome Sequence Of The SARS-Associated Coronavirus". Science 2003; 300:1399-1404
24. Merrifield RB, Solid phase synthesis. Science 1986; 232:341-347
25. Fields GB, et al., Chapter 3. "Principles and Practice Of Solid-Phase Peptide Synthesis". W.H. Freeman & Company, 1992:77-183
26. Harlow E, et al., Chapter 14. "Immunoassays. Antibodies A Laboratory Manual". Cold Spring Harbor Laboratory Press, 1988:553-612

27. Flaherty RJ, "Evidence-Based Medicine For Student Health Services". 2003: Montana State University, Bozeman.: <http://www.montana.edu/wwwwebm/URI.htm>



<b>INFORMATION DISCLOSURE CITATION</b> FORM PTO-1449		Attorney Docket: 1151-4175		Serial No.: 10/712,812			
		Applicant: Chang Yi Wang et al.					
		Filing Date: November 12, 2003		Group Art Unit: TBD			
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Patent Number	Issue Date	Name	Class	Sub-Class	Filing Date
		5,747,239	05/5/98	Wang et al.			
		6,048,538	04/11/00	Yi Wang et al.			
		5,639,594	06/17/97	Wang et al.			
		5,681,696	10/28/97	Wang			
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Patent Number	Publication Date	Country	Class	Sub-Class	Translation
							<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>OTHER DOCUMENTS (Including Author, Title, Date, etc.)</b>							
		Severe Acute Respiratory Disease: World Health Organization <a href="http://www.who.int/csr/sars/en">www.who.int/csr/sars/en</a> .					
		CDC. "Updated Interim Surveillance Case Definition for Severe Acute Respiratory Syndrome (SARS)"-- United States, April 29, 2003. <i>MMWR</i> 2003; 52:391-393					
		Fouchier RAM, et al., "Koch's Postulates Fulfilled for SARS Virus". <i>Nature</i> 2003; 423:240.					
		Peiris JSM, et al., "Coronavirus As a Possible Cause of Severe Acute Respiratory Syndrome". <i>Lancet</i> 2003; 361:1319-1325.					
		National Research Project for SARS Beijing Group. "Serum Antibodies Detection For Serological Diagnosis Of Severe Acute Respiratory Syndrome". <i>Zhonghua Jie He He Hu Xi Za Zhi</i> 2003; 26:339-342					
		Li G, et al., "Profile Of Specific Antibodies To The SARS-Associated Coronavirus". <i>N Eng J Med</i> 2003; 349:508-509.					
		Holmes KV, "Coronaviridae and Their Replication". <i>Virology</i> 2nd edition. Vol. 1. New York: Raven Press, 1990:841-864.					
		Rota PA, et al., "Characterization Of A Novel Coronavirus Associated With Severe Acute Respiratory Syndrome". <i>Science</i> 2003; 300:1394-1398					
		Ruan Y, et al., "Comparative Full-Length Genome Sequence Analysis Of 14 SARS Coronavirus Isolates And Common Mutations Associated With Putative Origins Of Infection". <i>Lancet</i> 2003; 361:1779-1785.					
		Wang Y, Xie Y, Chen W, "Immunoinformatic Analysis For The Epitopes On SARS Virus Surface Protein". <i>Beijing Da Xue Xue Bao</i> 2003; 35:70-71.					
		Yu H, et al., "Expression and Purification Of Recombinant SARS Coronavirus Spike Protein". <i>Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)</i> 2003; 35:774-778.					
		Elia G, et al., "Recombinant M Protein-Based ELISA Test For Detection Of Antibodies To Canine Coronavirus". <i>J Virol Methods</i> 2003; 109:139-142.					
		Che XY, et al., "Antibody Response Of Patients With Severe Acute Respiratory Syndrome (SARS) To Nucleocapsid Antigen Of SARS-Associated Coronavirus". <i>Di Yi Jun Yi Da Xue Xue Bao</i> 2003; 23:637-639.					
		Krokhin O, et al., "Mass Spectrometric Characterization Of Proteins From The SARS Virus". <i>Mol Cell Proteomics</i> 2003; 2:346-356.					





FORM PTO-1449

## INFORMATION DISCLOSURE CITATION

Attorney Docket:  
1151-4175Serial No.:  
10/712,812Applicant:  
Chang Yi Wang et al.Filing Date:  
November 12, 2003Group Art Unit:  
TBD

## OTHER DOCUMENTS (Including Author, Title, Date, etc.)

Wang CY, "Synthetic Peptide-Based Immunodiagnosis Of Retrovirus Infections: Current Status And Future Prospects". Synthetic peptides in biotechnology: 1988:131-148.

Wang JJG, et al., "Detection of Antibodies To Human T-Lymphotropic Virus Type III By Using A Synthetic Peptide Of 21 Amino Acid Residues Corresponding To A Highly Antigenic Segment Of Gp41 Envelope Protein". Proc Nat Acad Sci USA 1986; 83:6159-6163.

Hosein B, et al., "Improved Serodiagnosis Of Hepatitis C Virus Infection With Synthetic Peptide Antigen From Capsid Protein". Proc Nat Acad Sci USA 1991; 88:3647-3651.

Shen F, et al., "Differentiation of Convalescent Animals From Those Vaccinated Against Foot-And-Mouth Disease By A Peptide ELISA". Vaccine 1999; 17:3039-3049

Marra MA, et al., "The Genome Sequence Of The SARS-Associated Coronavirus". Science 2003; 300:1399-1404

Merrifield RB, Solid phase synthesis. Science 1986; 232:341-347.

Fields GB, et al., Chapter 3. "Principles and Practice Of Solid-Phase Peptide Synthesis". W.H. Freeman & Company, 1992:77-183

Harlow E, et al., Chapter 14. "Immunoassays. Antibodies A Laboratory Manual". Cold Spring Harbor Laboratory Press, 1988:553-612

Flaherty RJ, "Evidence-Based Medicine For Student Health Services". 2003: Montana State University, Bozeman.: <http://www.montana.edu/wwwwebm/URI.htm>.

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to Applicant.